Professor Nicholas D. Mazarakis holds the Lucas-Lee chair of Molecular BioMedicine and is head of Gene Therapy in Brain Sciences, Faculty of Medicine, Imperial College London. He is a molecular neuroscientist with an international reputation in gene therapy of neurological diseases. He has served as Vice President of Neurobiology at Oxford BioMedica plc, where he pioneered the first ever lentiviral gene therapy to the clinic for Parkinson’s disease (ProSavin®). His research focuses on investigating molecular pathways of neurodegeneration and developing translational gene therapies for neurological diseases. He received his Ph.D. from King’s College University of London and is an elected fellow of the Society of Biology. He has lectured in conferences worldwide and published in top science journals such as Nature, Science and PNAS. His research is supported by several grants including an Advanced Investigators award in 2008 and a Proof of Concept grant in 2013 from the European Research Council.
Researching more focused gene therapies for motor neurone diseases:
Imperial wins AHSC accreditation:
et al., 2016, PPAR gamma-coactivator-1 alpha gene transfer reduces neuronal loss and amyloid-beta generation by reducing beta-secretase in an Alzheimer's disease model, Proceedings of the National Academy of Sciences of the United States of America, Vol:113, ISSN:0027-8424, Pages:12292-12297
et al., 2014, Specific Retrograde Transduction of Spinal Motor Neurons using Lentiviral Vectors Targeted to Presynaptic NMJ Receptors, Molecular Therapy, Vol:22, ISSN:1525-0016, Pages:1285-1298
et al., 2014, Rabies Virus Envelope Glycoprotein Targets Lentiviral Vectors to the Axonal Retrograde Pathway in Motor Neurons, Journal of Biological Chemistry, Vol:289, ISSN:0021-9258, Pages:16148-16163